Sanofi's Dupixent Surpasses Xolair in Phase 4 Study for Chronic Rhinosinusitis with Asthma

Sanofi, in collaboration with Regeneron Pharmaceuticals, announced promising results from the EVEREST Phase 4 study. The study revealed that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps (CRSwNP) in patients also suffering from asthma. These findings were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress.

Dupixent exhibited superior performance across all efficacy endpoints related to CRSwNP and asthma. Significant improvements in nasal polyp size, sense of smell, and asthma control were reported within four weeks. The study involved 360 adults, with Dupixent showing a generally consistent safety profile compared to Xolair.

Results highlight Dupixent's effectiveness in targeting key inflammatory pathways, IL-4 and IL-13, providing vital insights for treatment strategies.